Chandra Bhagat Pharma Ltd Schedules Board Meeting for Capital Increase and Preferential Fundraising
Chandra Bhagat Pharma Limited has scheduled a meeting of its Board of Directors to address significant corporate actions, including an increase in authorized share capital and proposals for raising funds through preferential allotment.The Board Meeting is set to be held on Wednesday, August 5, 2026. The agenda items detailed for the meeting cover key strategic financial movements intended to support the company's growth objectives.
Among the principal points listed for consideration are the increasing of the Company's authorized share capital. Furthermore, the Board will consider a proposal related to fund raising through the issue of Equity Shares and convertible warrants or any other instruments. This fundraising mechanism would involve a Preferential allotment, open to be executed for either cash consideration or otherwise, subject to necessary shareholder approvals and applicable laws.
A third item on the agenda involves fixing the date, time, and place for an Extra Ordinary General Meeting (EOGM). The purpose of this EOGM will be to obtain shareholder approval for the aforementioned preferential issue and any other related business items.
In line with the Code of Conduct for prevention of insider trading, a specific trading restriction has been imposed. The trading window for all connected persons, designated employees, directors, and their immediate relatives shall remain closed starting from July 30, 2026. This closure period will continue until the conclusion of the Board Meeting plus 48 hours.
Stock Price Movement
As of 13:45, shares of Chandra Bhagat Pharma Ltd are ticking down 4.07% to ₹33.00 as the market runs through the afternoon trading session. The stock is completely locked at this price point, having seen no movement between its intraday high and low of ₹33.00.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.